arsenic trioxide has been researched along with simvastatin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aghamir, SMK; Akbari, MR; Khatami, F; Mirzaei, A; Rashedi, S | 1 |
1 review(s) available for arsenic trioxide and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for arsenic trioxide and simvastatin
| Article | Year |
|---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Combined anticancer effects of simvastatin and arsenic trioxide on prostate cancer cell lines via downregulation of the VEGF and OPN isoforms genes.
Topics: Apoptosis; Arsenic Trioxide; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Prostatic Neoplasms; Protein Isoforms; Simvastatin; Vascular Endothelial Growth Factor A | 2022 |